ARWR · Categories · M&A
ARWR - Mergers and acquisitions
Arrowhead Pharmaceuticals Inc. (ARWR) mergers and acquisitions - real-time wire coverage filtered to M&A only.
Recent M&A for ARWR
- Arrowhead Pharmaceuticals Acquires FDA Priority Review Voucher- Voucher to be used to accelerate review of a planned sNDA for plozasiran in severe hypertriglyceridemia Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) today announced that it has signed an agreement with an undisclosed third party to acquire a U.S. Food and Drug Administration (FDA) Rare Pediatric Disease Priority Review Voucher (PRV). The company intends to utilize the PRV for its upcoming Supplemental New Drug Application (sNDA) submission for plozasiran, anticipated before the end of 2026, to seek approval to expand the approved indication to include patients with severe hypertriglyceridemia (sHTG). SHTG is a condition that significantly increases the risk of acute pancreatitis, which
- Why Late-Stage CNS, Oncology Assets Are Becoming the Hottest Targets in Biotech M&AAUSTIN, Texas, Feb. 17, 2026 (GLOBE NEWSWIRE) -- BioMedWire Editorial Coverage: Biotech dealmaking is increasingly defined by a clear strategic shift: Pharmaceutical companies are prioritizing de-risked, late-stage assets with human clinical validation rather than speculative early-stage programs. After years of capital flowing into preclinical platforms with uncertain timelines, investors and acquirers are gravitating toward programs with established safety and efficacy data that can accelerate commercialization pathways. This evolving landscape naturally places companies such as Oncotelic Therapeutics Inc. (OTCQB:OTLC) (profile), which holds multiple clinical-stage and late-stage program
- Royalty Pharma Agrees to Acquire Royalty Interest in Olpasiran From Arrowhead for $250 million and Future MilestonesOlpasiran is an siRNA therapeutic being developed by Amgen to reduce risk of cardiovascular disease Arrowhead retains rights to $400 million in development, regulatory and sales milestone payments potentially due from Amgen from the 2016 out licensing agreement NEW YORK and PASADENA, Calif., Nov. 09, 2022 (GLOBE NEWSWIRE) -- Royalty Pharma plc (NASDAQ:RPRX) and Arrowhead today announced that Royalty Pharma has acquired a royalty interest in Amgen's olpasiran from Arrowhead Pharmaceuticals (NASDAQ:ARWR) for $250 million in cash upfront plus up to $160 million in additional payments contingent on the achievement of certain clinical, regulatory, and sales milestones. Olpasiran is a small i
- Arrowhead Sells Royalty Interest in Olpasiran to Royalty Pharma for $250 Million and Future Milestones- Olpasiran is an siRNA therapeutic being developed by Amgen to reduce risk of cardiovascular disease - Arrowhead retains rights to $400 million in development, regulatory, and sales milestone payments potentially due from Amgen from the 2016 out licensing agreement Arrowhead Pharmaceuticals Inc. (NASDAQ:ARWR) and Royalty Pharma plc (NASDAQ:RPRX) today announced that Royalty Pharma has acquired a royalty interest in Amgen's olpasiran from Arrowhead for $250 million in cash upfront plus up to $160 million in additional payments contingent on the achievement of certain clinical, regulatory, and sales milestones. Olpasiran is a small interfering RNA (siRNA) originally developed by Arrowhead